A01K 2267/0356
Animal model for processes and diseases of the central nervous system
Official title: Animal model for processes and diseases of the central nervous system, e.g. stress, learning, schizophrenia, pain, epilepsy
A01K2267/0356 (Animal model for processes and diseases of the central nervous system) appears on 247 US grants and 535 published applications in this corpus.
Search patents in A01K- Granted patents
- 247
- Published applications
- 535
- Assignees
- 240
- Inventors
- 997
- Latest grant
- 1 Sep 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1997 | 1 | 0 |
| 1998 | 6 | 0 |
| 1999 | 8 | 0 |
| 2000 | 7 | 0 |
| 2001 | 6 | 4 |
| 2002 | 7 | 38 |
| 2003 | 8 | 52 |
| 2004 | 11 | 22 |
| 2005 | 4 | 20 |
| 2006 | 10 | 45 |
| 2007 | 10 | 32 |
| 2008 | 5 | 25 |
| 2009 | 12 | 22 |
| 2010 | 9 | 28 |
| 2011 | 7 | 29 |
| 2012 | 12 | 11 |
| 2013 | 8 | 16 |
| 2014 | 8 | 8 |
| 2015 | 9 | 19 |
| 2016 | 11 | 16 |
| 2017 | 12 | 19 |
| 2018 | 10 | 18 |
| 2019 | 11 | 13 |
| 2020 | 10 | 15 |
| 2021 | 11 | 14 |
| 2022 | 5 | 14 |
| 2023 | 7 | 19 |
| 2024 | 12 | 13 |
| 2025 | 4 | 12 |
| 2026 | 6 | 11 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Rat models for CMT2A that develop a progressive neuropathy1 Sep 2026US 12,721,327 B2Charcot-Marie-Tooth Association
- Method for constructing murine model with mutations in csflr gene and application thereof14 Jul 2026US 12,677,811 B2Beijing Tiantan Hospital, Capital Medical University
- Humanized chimeras for the prospective assessment of cell addition and replacement therapies9 Jun 2026US 12,648,547 B2University of Copenhagen
- Genetically modified rat having PKHD1L1 gene with point mutation and methods for its construction, detection and use19 May 2026US 12,628,802 B2Huashan Hospital Affiliaed To Fudan University
- Antisense oligonucleotides targeting SCN2A for the treatment of SCN1A encephalopathies19 May 2026US 12,630,827 B2RogCon, Inc.
- Tight junction (zonulae occludentes) protein for use in treating or preventing epilepsy23 Jul 2026US 2026/0207706 A1The Provost, Fellows, Foundation Scholars and the other members of Board, of the College of the Holy
- Humanized chimeras for the prospective assessment of cell addition and replacement therapies16 Jul 2026US 2026/0198466 A1University of Copenhagen
- Biomarker for predicting risk of drug addiction relapse and animal model with high relapse of drug addiction9 Jul 2026US 2026/0193304 A1Korea Institute of Science and Technology
- Genetically modified rat having pkhd1l1 gene with point mutation and methods for its construction, detection and use2 Jul 2026US 2026/0182551 A1Huashan Hospital Affiliated To Fudan University
- Dystonia mouse models with overt dystonia11 Jun 2026US 2026/0157352 A1University of Florida Research Foundation, Inc.
Most cited
By later US patents
- Transgenic mice expressing APP-Swedish mutation develop progressive neurologic disease122US 5,877,399 ARegents of the University of Minnesota · 1999
- Method of using exendin and GLP-1 to affect the central nervous system79US 5,846,937 A1149336 Ontario Inc. · 1998
- Adeno-associated virus virions with variant capsid and methods of use thereof59US 9,457,103 B2The Regents of the University of California · 2016
- Transgenic rodents harboring APP allele having swedish mutation58US 5,850,003 AAthena Neurosciences, Inc. · 1998
- Optically controlled CNS dysfunction58US 8,932,562 B2The Board of Trustees of the Leland Stanford Junior University · 2015